The left atrial appendage exclusion for prophylactic stroke reduction (LEAAPS) trial: Rationale and design - 08/03/25
, Patrick M. McCarthy, MD c, Marc W. Gerdisch, MD d, Basel Ramlawi, MD e, John H. Alexander, MD, MHS f, Ibrahim Sultan, MD g, David Z. Rose, MD h, Jeffrey S. Healey, MD b, Yashasvi Awasthi Sharma, MS i, Emilie P. Belley-Côté, MD b, Stuart J. Connolly, MD b, †ABSTRACT |
Introduction |
Left atrial appendage exclusion (LAAE) has been shown in randomized trials to reduce ischemic stroke risk in patients undergoing cardiac surgery with known atrial fibrillation (AF). Many patients undergoing cardiac surgery without pre-existing AF are at risk of stroke and may benefit from LAAE.
Methods |
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction (LeAAPS) is an international, prospective, randomized, multicenter, blinded trial evaluating the effectiveness of LAAE in preventing ischemic stroke or systemic embolism in patients undergoing cardiac surgery at increased risk of AF and ischemic stroke. The trial will enroll 6500 patients at increased risk of stroke in whom a cardiac surgery is planned at 250 sites worldwide. Eligible patients are ≥18 years old, have no pre-existing AF but are at increased risk for AF and stroke (based on age, CHA2DS2-VASc score, left atrium size or brain natriuretic peptide). Patients are randomized 1:1 to receive either LAAE with AtriClip or no LAAE during cardiac surgery. Healthcare providers outside of the operating room and the patient will be blinded to allocation. The primary effectiveness endpoint is the first occurrence of ischemic stroke, systemic arterial embolism, or surgical or endovascular LAA closure. The powered secondary effectiveness endpoint is ischemic stroke or systemic arterial embolism. The primary safety endpoint is the occurrence of one of the following events (through 30 days): pericardial effusion requiring percutaneous or surgical treatment, peri-operative major bleeding, deep sternal wound infection, or myocardial infarction. Other endpoints include mortality, rehospitalizations, clinically diagnosed AF, transient ischemic attack, and cognitive and quality of life assessments. Follow-up is every 6 months for a minimum of 5 years; primary analysis occurs when 469 patients have had an ischemic stroke or systemic embolism.
Conclusion |
The results of the LeAAPS trial will demonstrate whether LAAE with AtriClip at the time of other routine cardiac surgery reduces stroke or systemic arterial embolism during long-term follow-up in patients at high risk of stroke without pre-existing AF.
Trial Registration |
ClinicalTrials.gov, Identifier: NCT05478304, NCT05478304?term=%20NCT05478304&rank=1.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 284
P. 94-102 - Giugno 2025 Ritorno al numero
Articolo precedente
- Occult cancer in patients with unprovoked venous thromboembolism: Rationale, design, and methods of the VaLRIETEs study and the SOME-RIETE trial
- Maria Barca-Hernando, Sonia Otalora-Valderrama, Juan Jose Lopez-Nuñez, Jose Portillo-Sanchez, Javier Pagan-Escribano, Patricia Lopez-Miguel, Isabelle Mahe, Elisabeth Mena-Muñoz, Ines Jou-Segovia, Egidio Imbalzano, Paloma Agudo-de Blas, Alicia Lorenzo-Hernandez, Carmen Diaz-Pedroche, Jesus Aibar-Gallizo, Gloria de la Red-Bellvis, Fatima del Molino-Sanz, Cristina Amado-Fernandez, Jose Luis Fernandez-Reyes, Aurora Villalobos-Sanchez, Juan Bosco Lopez-Saez, Ana Maria Diaz-Brasero, Maria Marcos-Jubilar, Jose Meireles, Pablo Javier Marchena-Yglesias, Jose Antonio Diaz-Peromingo, Samira Marin-Romero, Teresa Elias-Hernandez, Henry A Andrade-Ruiz, Ghazaleh Mehdipour, Behnood Bikdeli, Luis Jara-Palomares, The SOME-RIETE and ValRIETEs Investigators
- Pharmaco-invasive strategy and dosing of tenecteplase in STEMI patients 60 to <75 years: An inter-trial comparison of the STREAM-1 and STREAM-2 trials
- Kevin R. Bainey, Robert C. Welsh, Yinggan Zheng, Alexandra Arias-Mendoza, Arsen D. Ristić, Oleg V. Averkov, Yves Lambert, Tracy Temple, Eric Ly, Kris Bogaerts, Peter Sinnaeve, Cynthia M. Westerhout, Frans Van de Werf, Paul W. Armstrong, STREAM-2 Investigators
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?